Moody National Bank Trust Division Takes $1.07 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Moody National Bank Trust Division bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, HoldingsChannel reports. The fund bought 1,498 shares of the biopharmaceutical company’s stock, valued at approximately $1,067,000.

A number of other large investors also recently modified their holdings of REGN. Rakuten Securities Inc. raised its holdings in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $26,000. Fairfield Financial Advisors LTD bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $37,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $39,000. Finally, Truvestments Capital LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at $39,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $716.90 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20. The company’s 50 day moving average price is $749.20 and its two-hundred day moving average price is $958.71. The firm has a market cap of $78.78 billion, a PE ratio of 17.74, a PEG ratio of 2.19 and a beta of 0.10. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 target price for the company. Citigroup assumed coverage on Regeneron Pharmaceuticals in a report on Thursday, November 14th. They set a “neutral” rating and a $895.00 price target for the company. BMO Capital Markets dropped their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Finally, Piper Sandler reduced their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,037.33.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.